Skip to main content
Springer logoLink to Springer
. 2020 Jun 9;39(11):2185–2194. doi: 10.1007/s10096-020-03925-5

Staphylococcus capitis isolated from bloodstream infections: a nationwide 3-month survey in 38 neonatal intensive care units

Marie Decalonne 1, Sandra Dos Santos 2, Rémi Gimenes 1, Florent Goube 1, Géraldine Abadie 3, Saïd Aberrane 4, Vanina Ambrogi 5, Raoul Baron 6, Patrick Barthelemy 7, Isabelle Bauvin 8, Olivier Belmonte 9, Emilie Benabid 10, Rafik Ben Ammar 11, Salma Ben Hadj Yahia 12, Yasmina Berrouane 13, Philippe Berthelot 14, Alain Beuchee 15, Emmanuelle Bille 16, Pascal Bolot 17, Stéphanie Bordes-Couecou 18, Antoine Bouissou 19, Sandra Bourdon 20, Nadège Bourgeois-Nicolaos 21, Sophie Boyer 22, Christian Cattoen 23, Vincent Cattoir 24, Chantal Chaplain 25, Céline Chatelet 26, Aurore Claudinon 27, Nathalie Chautemps 28, Hélène Cormier 29, Céline Coroller-Bec 30, Benjamin Cotte 31, Carole De Chillaz 32, Olivier Dauwalder 33, Aude Davy 34, Martine Delorme 35, Maryvonne Demasure 36, Luc Desfrere 37, Michel Drancourt 38, Clarisse Dupin 39, Véronique Faraut-Derouin 40, Arnaud Florentin 41, Virginie Forget 42, Nicolas Fortineau 43, Tania Foucan 44, Pierre Frange 16,45, Karine Gambarotto 46, Géraldine Gascoin 47, Laure Gibert 20, Jacques Gilquin 48, Audrey Glanard 49, Jacqueline Grando 50, Alain Gravet 51, Jérôme Guinard 52, Geneviève Hery-Arnaud 53, Claire Huart 54, Nadia Idri 55,56, Jean-Marc Jellimann 57, Olivier Join-Lambert 58, Sylvie Joron 59, Philippe Jouvencel 60, Marie Kempf 61, Sophie Ketterer-Martinon 62, Mouna Khecharem 63, Serge Klosowski 64, Franck Labbe 65, Adeline Lacazette 66, Fabrice Lapeyre 67, Jérôme Larche 68, Peggy Larroude 69, Anne Le Pourhiennec 70, Nolwenn Le Sache 71, Sylvie Ledru 72, Annick Lefebvre 73, Clément Legeay 29, Florence Lemann 74, Claire Lesteven 75, Marion Levast-Raffin 76, David Leyssene 77, Isabelle Ligi 78, Alain Lozniewski 79, Pierre Lureau 80, Franck-Olivier Mallaval 42, Edith Malpote 81, Stéphane Marret 82, Pascale Martres 83, Guillaume Menard 84, Laura Menvielle 85, Laurent Mereghetti 86, Véronique Merle 87, Pascale Minery 88, Virginie Morange 89, Julien Mourdie 90, Anaelle Muggeo 91, Jean Nakhleh 92, Marie-Noëlle Noulard 93, Claude Olive 94, Hugues Patural 95, Pascale Penn 96, Manuel Petitfrere 97, Bruno Pozetto 98, Brigitte Riviere 99, Audrey Robine 100, Christine Roques Ceschin 5, Raymond Ruimy 101, Amine Siali 102, Stéphanie Soive 103, Souad Slimani 104, Anne-Sophie Trentesaux 105, Dominique Trivier 26, Christian Vandenbussche 106, Laurent Villeneuve 107, Evelyne Werner 108, Stéphane Le Vu 109, Nathalie Van Der Mee-Marquet 1,2,
PMCID: PMC7561542  PMID: 32519215

Abstract

To increase the knowledge about S. capitis in the neonatal setting, we conducted a nationwide 3-month survey in 38 neonatal intensive care units (NICUs) covering 56.6% of French NICU beds. We demonstrated 14.2% of S. capitis BSI (S.capBSI) among nosocomial BSIs. S.capBSI incidence rate was 0.59 per 1000 patient-days. A total of 55.0% of the S.capBSIs were late onset catheter-related BSIs. The S. capitis strains infected preterm babies (median gestational age 26 weeks, median birth weight 855 g). They were resistant to methicillin and aminoglycosides and belonged to the NRCS-A clone. Evolution was favorable in all but one case, following vancomycin treatment.

Keywords: Staphylococcus capitis, NRCS-A clone, Bloodstream catheter-related infection, Neonatal Intensive Care Unit (NICU), Preterm babies, Neonates, Nationwide active surveillance

Introduction

Catheter-related bloodstream infections (CRBSI) are associated with increased rates of morbidity in intensive care unit patients and in neonates [1]. The prevention of the avoidable part of CRBSIs is a public health priority [2, 3]. In this context, since 2019, all French hospitals and clinics are encouraged to participate in an annual 3-month survey of CRBSI coordinated by the national infection control SPIADI network. Over the last two decades, multidrug-resistant Staphylococcus capitis has been increasingly reported as a major agent responsible for CRBSI in preterm babies [4]. Therapeutic failures likely due to heteroresistance to vancomycin in this bacteria [5] and local epidemics have been identified and investigated in NICUs [57]. S. capitis seems to be particularly well-adapted to the NICU environment, possibly in connection with its ability to produce biofilm [8, 9]. However, the neonate contamination routes remain obscure. Recent studies performed in distinct parts of the world have demonstrated a single lineage within the S. capitis species, named NRCS-A, responsible for invasive neonatal infections worldwide [10, 11]. The mechanisms that have driven the global dissemination of this clone have not yet been elucidated. We report the results of the 3-month nationwide BSI survey conducted during the first quarter of 2019 in the largest series of NICUs located in 38 French hospitals. We present clinical data related to the neonates suffering from BSI, and the incidence rates and major characteristics of the neonatal BSIs. In addition, using molecular methods, we characterized the isolates responsible for S. capitis BSIs to establish whether or not they belong to the NRCS-A clone. We provide new data that increase the knowledge about S. capitis in the current neonatal setting.

Materials and methods

BSI epidemiological survey method

Study population

Thirty-eight maternity hospitals comprising neonatal intensive beds participated in the study (Fig. 1). The 447 beds surveyed represented 56.6% of French neonatal intensive beds (https://www.data.gouv.fr/en/datasets/).

Fig. 1.

Fig. 1

Location of the 38 participating centers and number of neonatal intensive care beds

Study design

The surveillance program involved a 3-month survey of all cases of nosocomial BSI between January 1 and April 30 2019. The survey covered 33,971 intensive care patient-days (PD). Nosocomial BSIs were defined according to international definitions (CDC). The variables studied included clinical data (i.e., sex, gestational age, birth weight, death within 7 days of BSI diagnosis), major characteristics of the BSI such as the portal of entry (skin [primitive cutaneous form or superinfection of a skin breach], lungs, urine, intravascular device, or digestive tract), and for catheter-related BSI, the time lag between the insertion of the catheter, and the appearance of the clinical signs of the BSI. The BSI incidence rates were calculated per 1000 PD. Ethical approval of the surveillance program was obtained at the national level from the Réseau de Prévention des Infections Associées aux Soins.

Microbiological study

PFGE was used as a typing technique [12].

Statistical data

The data were analyzed with R software. Chi-square tests and Fisher’s exact test (two-tailed) were used to test associations, and a P value of 0.05 was considered significant.

Results

Epidemiology of neonatal BSI

During the study period, 141 nosocomial BSIs were diagnosed in 81 male and 60 female neonates. The mean BSI incidence rate was 4.15 per 1000 PD (Table 1). The most frequently isolated micro-organisms were S. epidermidis (39.0%), S. aureus (17.0%), S. haemolyticus (15.6%), and S. capitis (14.2%). Twenty BSIs were polymicrobial (14.2%).

Table 1.

BSI, B-cvc, and B-uvc incidence rates per 1000 PD according to the participating centers

enters BSI incidence rates per 1000 PD
During the 3-month survey BSI B-cvc B-uvc
PD Nosocomial BSI All S. aureus S. epidermidis S. capitis Enterobacteriaceae All S. aureus B-cvc S. capitis B-cvc All
Participating centers with a neonatal intensive care unit
  University regional hospitals
   1 2,443 10 4.09 0.82 2.45 0.41 0.00 1.64 0.41 0.41 2.46
   2 1,840 7 3.80 1.09 0.54 0.00 1.63 1.63 0.54 0.00 0.54
   3 1,825 10 5.48 2.19 1.64 0.00 0.55 0.00 0.00 0.00 0.00
   4 1,658 14 8.44 2.41 4.22 0.60 0.60 3.01 1.21 0.60 0.60
   5 1,482 6 4.05 0.67 0.00 2.02 0.00 1.35 0.67 0.67 0.00
   6 1,332 8 6.01 0.00 3.00 1.50 1.50 3.00 0.00 0.75 1.50
   7 1,322 10 7.56 0.76 3.02 0.76 0.76 0.00 0.00 0.00 0.00
   8 1,204 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   9 1,134 8 7.05 0.00 2.64 1.76 0.00 3.53 0.00 0.88 0.88
   10 1,114 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   11 1,062 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   12 1,023 6 5.86 0.00 2.93 0.98 0.00 0.98 0.00 0.98 1.95
   13 1,016 3 2.97 0.98 0.98 0.98 0.00 0.98 0.00 0.00 0.98
   14 999 3 3.00 0.00 2.00 0.00 0.00 1.00 0.00 0.00 0.00
   15 892 4 4.48 0.00 1.12 2.24 1.12 2.24 0.00 1.12 1.12
   16 822 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   17 764 5 6.54 1.31 3.93 1.31 0.00 2.62 0.00 0.00 0.00
   18 793 5 6.31 1.26 2.52 1.26 0.00 3.78 0.00 1.26 0.00
   19 636 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   20 545 4 11.00 0.00 0.00 0.00 1.83 5.50 0.00 0.00 1.83
   21 524 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
  General hospitals
   22 972 3 3.09 1.03 1.03 1.03 0.00 2.06 1.03 1.03 1.03
   23 893 1 1.12 0.00 0.00 1.12 0.00 1.12 0.00 1.12 0.00
   24 890 5 5.62 2.25 2.25 1.12 1.12 1.12 1.12 0.00 1.12
   25 769 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   26 753 6 7.97 3.98 0.00 1.33 2.66 1.33 1.33 0.00 0.00
   27 595 2 3.36 0.00 1.68 0.00 0.00 1.68 0.00 0.00 0.00
   28 570 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   29 493 6 12.20 0.00 6.08 0.00 0.00 2.03 0.00 0.00 10.14
   30 401 0 0.00 0.00 0.00 0.00 0.00 0,00 0.00 0.00 0.00
   31 396 1 2.52 0.00 2.52 0.00 0.00 2.52 0.00 0.00 0.00
   32 369 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   33 353 2 2.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   34 320 3 9.38 0.00 6.25 0.00 3.12 0.00 0.00 0.00 0.00
   35 308 7 22.72 0.00 9.74 0.00 6.49 9.74 0.00 0.00 0.00
   36 275 2 7.27 3.64 0.00 0.00 3.64 3.64 3.64 0.00 0.00
Participating centers with intensive care beds in neonatal medical unit
  General hospital
   22 854 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   Private clinic
   40 330 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
   All 33,971 141 4.15 0.71 1.62 0.59 0.50 1.38 0.26 0.29 0.68

The portal of entry of the BSIs was suspected or proven in 83.7% of the cases. The digestive tract (12.1%), the skin (8.5%), and the pulmonary tract (6.4%) were minor portals of entry. Most of the BSIs were catheter-related (70 CRBSIs; 50.0 %) (Table 2). The CRBSI involved a central venous catheter (CVC) in 47 cases (67.1%), all but one associated with staphylococci (97.9%), and an umbilical venous catheter (UVC) in 23 cases (32.9%). The UVC-related BSIs were more diverse than those related to CVC: enterococci-, Enterobacteriaceae-, and B. cereus-BSIs were more frequent with UVC-BSIs (26.1%) rather than with CVC-BSIs (4.3%) (p = 0.022). The median time lag between the insertion of the catheter and the appearance of the clinical signs of the BSI was significantly longer for S. capitis (63.6%, ≥ 10 days) rather than for S. aureus (7.7%), S. epidermidis (16.1%), S. haemolyticus (30.8%), enterococci, and Enterobacteriaceae (no case) (p = 0.018; Table 3).

Table 2.

Major characteristics of the BSIs and infected neonates according to the micro-organism

BSIs Infected neonates
N Portal of entry Sex Birth weight (g) Gestational age (week) Early death (%)
CVC UVC Cutaneous Pulmonary Urinary Digestive Others Not identified Male Female < 1500 g Median < 33 weeks Median
Micro-organism
   All 141 47 23 12 9 1 17 9 23 81 60 112 (79.4) 980 113 (80.1) 28 22 (15.6)
   S. aureus 24 9 4 4 4 1 1 1 12 12 16 (66.7) 1,100 16 (66.7) 30 7 (29.2)
   S. epidermidis 55 20 11 6 1 4 1 12 35 20 43 (78.2) 910 43 (78.2) 27 5 (9.1)
   S. haemolyticus 22 10 3 2 3 1 3 10 12 22 (100.0) 917 21 (95.4) 27 3 (13.6)
   S. capitis 20 10 1 1 1 3 4 12 8 16 (80.0) 855 15 (75.0) 26 1 (5.0)
   Enterococci 7 1 3 1 1 1 6 1 4 (57.1) 1,260 4 (57.1) 31 1 (14.3)
   Enterobacteriaceae 17 1 2 2 1 4 5 2 9 8 9 (52.9) 1,480 11 (64.7) 29 5 (29.4)
   Bacillus cereus 3 1 1 1 0 3 2 (66.7) 745 3 (100.0) 28 0

Table 3.

Time lag between the insertion of the catheter and the appearance of the clinical signs of the CRBSI

Number of CRBSIs Time lag (days)
Mean Median < 10 days ≥ 10 days
Micro-organism
   S. aureus 13 7.2 6 11 3
   S. epidermidis 31 8.0 6 26 5
   S. haemolyticus 13 8.1 6 9 4
   S. capitis 10 10.3 10 4 7
   Enterococci 4 6.2 6 4 0
   Enterobacteriaceae 3 4 4 3 0

Characteristics of the infected neonates

The gestational age of the infected neonates ranged between 24 and 41 weeks (median value 28), and their birth weight ranged between 455 and 4050 g (median value 1100); 15.6% of the neonates died during the 7-day period after the diagnosis of the BSI. BSIs involving S. aureus, Enterobacteriaceae, and Enterococci were associated with the highest prevalence of early death among infected neonates (29.4, 29.2, and 14.3% for Enterobacteriaceae-, S. aureus-, and Enterococci-associated BSIs, respectively). The prevalence of BSI in the neonates with the a gestational age ≥ 33 weeks and a birth weight > 1500 g differed according to the bacteria (Table 2): it was the highest for Enterococci (42.9%), Enterobacteriaceae (35.3%), and S. aureus (29.2%), lower for S. capitis (20.0%) and E. epidemidis (18.2%) and nil for S. haemolyticus and B. cereus (p = 0.056).

S. capitis BSI characteristics and antibiotic susceptibility of S. capitis strains

Twenty BSIs were associated with S. capitis (14.2%), resulting in a mean incidence of 0.59 per 1000 PD, ranging between 0 and 2.24 according to centers (Table 1); 39.5% of the NICUs reported at least one S. capitis-BSIs. The S. capitis-BSIs were significantly associated with the largest NICUs: at least one S. capitis-BSIs was reported in 15 of the 22 NICUs with ≥ 10 beds, whereas none was reported in the 14 NICUs with < 10 beds (p < 0.001). Four NICUs documented two (n = 3) or three (n = 1) S. capitis-BSIs during the survey period. The antibiotic susceptibility patterns of 18 strains were available (90.0%). Most of the strains were resistant to multiple antibiotics, i.e., methicillin (100%), gentamicin (100%), rifampicin (61.1%), fosfomycin (55.5%), erythromycin (44.4%), fluoroquinolones (33.3%), and fusidic acid (22.2%). Vancomycin and teicoplanin MIC values ranged between 0.25 and 4 mg/L (Table 4). Data regarding antibiotic treatment were available for 18 cases: 17 neonates received vancomycin over 2–24 days (median value: 8 days) and the remaining neonate received linezolid (11 days). A favorable outcome was observed in all but one case. An early death was observed for a preterm infected neonate (gestational age 25 weeks; birth weight 455 g), who received vancomycin over 3 days following the detection of a S. capitis and S. haemolyticus-associated CRBSI.

Table 4.

Antibiotic susceptibility of the S. capitis strains

Centers Strain Antibiotype* MIC vancomycine (mg/L) MIC teicoplanine (mg/L)
1 1 Oxa KTG Ri Fu 0.5 < 0.25
9 2 Oxa KTG Ri Fo 0.5 < 0.25
3 Oxa KTG Ri Fo 0.5 < 0.25
4 4 Oxa KTG Ri Fo
7 5 Oxa AKTG Ri Fu Ery
13 6 Oxa TG Nor 1 2
6 7 Oxa G Cip Ery Ri < 4 < 2
8 Oxa G Cip Ery < 4 < 2
5 9 Oxa ATG Ri Fo Te(I) Ery(I) Pr(I) 1 0.5
10 Oxa ATG Ri Fo Te(I) Ery(I) Pr(I) 1 0.5
11 Oxa ATG Ri Fo Te(I) Ery(I) Pr(I) 1 0.5
15 12 Oxa ATG Cip Fo 1 2
13 Oxa ATG Cip Fo 1 1
17 14 Oxa AKTG Cip Fo 1 1
12 15 Oxa KTG Ery 2 4
22 16 Oxa AKTG 0.5 < 0.25
18 17 Oxa ATG Ri Fu 0.5 < 0.25
26 20 Oxa ATG Ri Fo Te(I) Ery(I) Pr(I) 1 2

Oxa oxacillin, K kanamycin, T tobramycin, G gentamicin, A amikacin, Ri Rifampicin, Fu fusidic acid, Fo fosfomycin, Te tetracyclin, Ery erythromycin, Pr pristinamycin, Nor norfloxacin, Cip ciprofloxacin

Twelve S. capitis BSI strains from 8 NICUs were available for molecular typing. A considerable homogeneity was demonstrated among the strains, and PFGE pattern analysis demonstrated that all strains belonged to the NRCS-A clone [10] (Fig. 2). Regarding the three NICUs that reported several S. capitis-BSI cases, the strains isolated in a same center shared the same pattern in two cases. In addition, the strains isolated from three distinct centers located in two distant French regions shared the same pattern.

Fig. 2.

Fig. 2

SmaI PFGE patterns of the S. capitis strains responsible for neonatal BSI

Discussion

This nationwide study adds several elements to the available data on S. capitis responsible for neonatal BSI.

We provide a first mean incidence of S. capitis BSIs in French NICUs. S. capitis BSIs currently involve an average of one neonate per 1700 PD, which is lower than that observed for S. aureus and S. epidermidis, but higher than that of Enterobacteriaceae in the population of neonates surveyed. Our findings confirm S. capitis as a significant agent responsible for nosocomial BSI in the neonatal setting [10, 11, 13].

Second, such as S. epidermidis and S. haemolyticus, we showed that S. capitis preferentially infects the more fragile neonates and thus confirmed that S. capitis is an opportunistic pathogen, devoid of great virulence potential. Concordant with previous studies [13], all the S. capitis strains responsible for BSIs displayed resistance to methicillin and gentamicin, but remained susceptible to vancomycin. S. capitis-BSIs have been taken into account by the clinicians, and vancomycin probably played a crucial role in the recovery of neonates.

Third, we identified one particularity distinguishing S. capitis among the bacteria associated with CRBSI cases. Our study reveals a doubled lag time between insertion of the catheter and the first signs of the BSI involving S. capitis when compared with other bacteria. The absence of early infection likely excludes a contamination of the catheter at the time of its insertion, but rather indicates that the contamination of the catheter may have occurred following catheter manipulations among neonates presenting the longest periods of catheterization.

Finally, the molecular analysis of a large part of the S. capitis strains indicates that they belong to the multidrug-resistant NRCS-A clone and highly suggests likely epidemic phenomena among the NICUs presenting the highest incidence rates of S. capitis BSIs.

Conclusion

Our data confirm the clone NRCS-A particularly well-suited to the neonatal setting and its cumbersome epidemiology [10, 11, 13]. In most NICUs, S. capitis BSIs remain relatively infrequent among neonates, but concern primarily the most fragile ones. In order to better determine the factors involved in the occurrence of these infections, monitoring of BSIs should be continued and complemented by a systematic investigation when several cases are identified over a 3-month period in the same NICU.

Authors’ contribution

MD conducted the study, SDS performed the molecular typing, RM conducted the statistical analysis, FG designed and developed the website for data collection and analysis, SLV participated with the data analysis, NVDM designed and conducted the study and wrote the manuscript.

All the others are participating members from each of the 41 NICUs (the infection control practitioner, the microbiologist, and the clinician responsible for the NICU). They collected the data and strains.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The nationwide survey was conducted under the control of the national agency Santé Public France and with the authorization by the CNIL (a national committee for data protection). Ethical review and approval was not required for the study on human participants in accordance with the French national legislation and institutional requirements.

Informed consent

In each participating hospital, a quality commitment charter was signed by the general director and the infection control physician. Patients were informed and ask for consent about the 3-month national survey.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol. 2011;32(2):101–114. doi: 10.1086/657912. [DOI] [PubMed] [Google Scholar]
  • 2.Gastmeier P, Geffers C. Prevention of catheter-related bloodstream infections: analysis of studies published between 2002 and 2005. J Hosp Infect. 2006;64(4):326–335. doi: 10.1016/j.jhin.2006.07.005. [DOI] [PubMed] [Google Scholar]
  • 3.Schreiber PW, Sax H, Wolfensberger A, Clack L, Kuster SP. The preventable proportion of healthcare-associated infections 2005-2016: Systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2018;39(11):1277–1295. doi: 10.1017/ice.2018.183. [DOI] [PubMed] [Google Scholar]
  • 4.Laurent F, Butin M. Staphylococcus capitis and NRCS-A clone: the story of an unrecognized pathogen in neonatal intensive care units. Clin Microbiol Infect. 2019;25(9):1081–1085. doi: 10.1016/j.cmi.2019.03.009. [DOI] [PubMed] [Google Scholar]
  • 5.van der Zwet WC, Debets-Ossenkopp YJ, Reinders E, Kapi M, Savelkoul PHM, van Elburg RM, et al. Nosocomial spread of Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit. J Clin Microbiol. 2002;40:2520–2525. doi: 10.1128/JCM.40.7.2520-2525.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.De Silva GD, Justice A, Wilkinson AR, Buttery J, Herbert M, Day NP, et al. Genetic population structure of coagulase-negative staphylococci associated with carriage and disease in preterm infants. Clin Infect Dis. 2001;33:1520–1528. doi: 10.1086/323338. [DOI] [PubMed] [Google Scholar]
  • 7.Gras-Le Guen C, Fournier S, Andre-Richet B, Caillon J, Chamoux C, Espaze E, et al. Almond oil implicated in a Staphylococcus capitis outbreak in a neonatal intensive care unit. J Perinatol. 2007;27:713–717. doi: 10.1038/sj.jp.7211798. [DOI] [PubMed] [Google Scholar]
  • 8.Qu Y, Daley AJ, Istivan TS, Garland SM, Deighton MA. Antibiotic susceptibility of coagulase-negative staphylococci isolated from very low birth weight babies: comprehensive comparisons of bacteria at different stages of biofilm formation. Ann Clin Microbiol Antimicrob. 2010;9:16. doi: 10.1186/1476-0711-9-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cui B, Smooker PM, Rouch DA, Daley AJ, Deighton MA. Differences between two clinical Staphylococcus capitis subspecies as revealed by biofilm, antibiotic resistance, and pulsed-field gel electrophoresis profiling. J Clin Microbiol. 2013;51(1):9–14. doi: 10.1128/JCM.05124-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Butin M, Rasigade JP, Martins-Simöes P, Meugnier H, Lemriss H, Goering RV, et al. Wide geographical dissemination of the multiresistant Staphylococcus capitis NRCS-A clone in neonatal intensive care units. Clin Microbiol Infect. 2016;22:46–52. doi: 10.1016/j.cmi.2015.09.008. [DOI] [PubMed] [Google Scholar]
  • 11.Carter GP, Ussher JE, da Silva GD, Baines SL, Heffernan H, Riley TV et al (2018) Genomic analysis of multiresistant Staphylococcus capitis associated with neonatal sepsis. Antimicrob Agents Chemother 62(11). 10.1128/AAC.00898-18 [DOI] [PMC free article] [PubMed]
  • 12.Murchan S, Kaufmann ME, Deplano A, de Ryck R, Struelens M, Zinn CE, et al. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol. 2003;41:1574–1585. doi: 10.1128/JCM.41.4.1574-1585.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Stenmark B, Hellmark B, Söderquist B. Genomic analysis of Staphylococcus capitis isolated from blood cultures in neonates at a neonatal intensive care unit in Sweden. Eur J Clin Microbiol Infect Dis. 2019;38(11):2069–2075. doi: 10.1007/s10096-019-03647-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from European Journal of Clinical Microbiology & Infectious Diseases are provided here courtesy of Springer

RESOURCES